1
|
Merseburg A, Kasemir J, Buss EW, Leroy F, Bock T, Porro A, Barnett A, Tröder SE, Engeland B, Stockebrand M, Moroni A, Siegelbaum S, Isbrandt D, Santoro B. Seizures, behavioral deficits and adverse drug responses in two new genetic mouse models of HCN1 epileptic encephalopathy. eLife 2022; 11:70826. [PMID: 35972069 PMCID: PMC9481245 DOI: 10.7554/elife.70826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Accepted: 08/15/2022] [Indexed: 11/13/2022] Open
Abstract
De novo mutations in voltage- and ligand-gated channels have been associated with an increasing number of cases of developmental and epileptic encephalopathies, which often fail to respond to classic antiseizure medications. Here, we examine two knock-in mouse models replicating de novo sequence variations in the HCN1 voltage-gated channel gene, p.G391D and p.M153I (Hcn1G380D/+ and Hcn1M142I/+ in mouse), associated with severe drug-resistant neonatal- and childhood-onset epilepsy, respectively. Heterozygous mice from both lines displayed spontaneous generalized tonic-clonic seizures. Animals replicating the p.G391D variant had an overall more severe phenotype, with pronounced alterations in the levels and distribution of HCN1 protein, including disrupted targeting to the axon terminals of basket cell interneurons. In line with clinical reports from patients with pathogenic HCN1 sequence variations, administration of the antiepileptic Na+ channel antagonists lamotrigine and phenytoin resulted in the paradoxical induction of seizures in both mouse lines, consistent with an effect to further impair inhibitory neuron function. We also show that these variants can render HCN1 channels unresponsive to classic antagonists, indicating the need to screen mutated channels to identify novel compounds with diverse mechanism of action. Our results underscore the necessity of tailoring effective therapies for specific channel gene variants, and how strongly validated animal models may provide an invaluable tool towards reaching this objective.
Collapse
Affiliation(s)
- Andrea Merseburg
- Experimental Neurophysiology, German Center for Neurodegenerative Diseases, Bonn, Germany
| | - Jacquelin Kasemir
- Experimental Neurophysiology, German Center for Neurodegenerative Diseases, Bonn, Germany
| | - Eric W Buss
- Department of Neuroscience, Columbia University, New York, United States
| | - Felix Leroy
- Department of Neuroscience, Columbia University, New York, United States
| | - Tobias Bock
- Department of Neuroscience, Columbia University, New York, United States
| | | | - Anastasia Barnett
- Department of Neuroscience, Columbia University, New York, United States
| | - Simon E Tröder
- Faculty of Medicine, University of Cologne, Cologne, Germany
| | - Birgit Engeland
- Experimental Neurophysiology, German Center for Neurodegenerative Diseases, Bonn, Germany
| | - Malte Stockebrand
- Experimental Neurophysiology, German Center for Neurodegenerative Diseases, Bonn, Germany
| | - Anna Moroni
- Department of Biosciences, University of Milan, Milan, Italy
| | - Steve Siegelbaum
- Department of Neuroscience, Columbia University, New York, United States
| | - Dirk Isbrandt
- Experimental Neurophysiology, German Center for Neurodegenerative Diseases, Cologne, Germany
| | - Bina Santoro
- Department of Neuroscience, Columbia University, New York, United States
| |
Collapse
|
2
|
Santoro B, Shah MM. Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels as Drug Targets for Neurological Disorders. Annu Rev Pharmacol Toxicol 2020; 60:109-131. [PMID: 31914897 DOI: 10.1146/annurev-pharmtox-010919-023356] [Citation(s) in RCA: 57] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are voltage-gated ion channels that critically modulate neuronal activity. Four HCN subunits (HCN1-4) have been cloned, each having a unique expression profile and distinctive effects on neuronal excitability within the brain. Consistent with this, the expression and function of these subunits are altered in diverse ways in neurological disorders. Here, we review current knowledge on the structure and distribution of the individual HCN channel isoforms, their effects on neuronal activity under physiological conditions, and how their expression and function are altered in neurological disorders, particularly epilepsy, neuropathic pain, and affective disorders. We discuss the suitability of HCN channels as therapeutic targets and how drugs might be strategically designed to specifically act on particular isoforms. We conclude that medicines that target individual HCN isoforms and/or their auxiliary subunit, TRIP8b, may provide valuable means of treating distinct neurological conditions.
Collapse
Affiliation(s)
- Bina Santoro
- Department of Neuroscience, Columbia University, New York, NY 10027, USA
| | - Mala M Shah
- Department of Pharmacology, School of Pharmacy, University College London, London WC1N 1AX, United Kingdom;
| |
Collapse
|
3
|
Sivilia S, Mangano C, Beggiato S, Giuliani A, Torricella R, Baldassarro VA, Fernandez M, Lorenzini L, Giardino L, Borelli AC, Ferraro L, Calzà L. CDKL5 knockout leads to altered inhibitory transmission in the cerebellum of adult mice. GENES BRAIN AND BEHAVIOR 2016; 15:491-502. [DOI: 10.1111/gbb.12292] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Revised: 03/20/2016] [Accepted: 04/02/2016] [Indexed: 12/29/2022]
Affiliation(s)
- S. Sivilia
- Department of Veterinary Medical Science; University of Bologna; Bologna
| | - C. Mangano
- Department of Veterinary Medical Science; University of Bologna; Bologna
| | - S. Beggiato
- Department of Medical Sciences; University of Ferrara; Ferrara
| | - A. Giuliani
- Department of Veterinary Medical Science; University of Bologna; Bologna
| | - R. Torricella
- Health Science and Technologies Interdepartmental Center for Industrial Research (HST-ICIR); University of Bologna; Bologna
| | - V. A. Baldassarro
- Health Science and Technologies Interdepartmental Center for Industrial Research (HST-ICIR); University of Bologna; Bologna
| | - M. Fernandez
- Health Science and Technologies Interdepartmental Center for Industrial Research (HST-ICIR); University of Bologna; Bologna
| | - L. Lorenzini
- Health Science and Technologies Interdepartmental Center for Industrial Research (HST-ICIR); University of Bologna; Bologna
| | - L. Giardino
- Department of Veterinary Medical Science; University of Bologna; Bologna
- Health Science and Technologies Interdepartmental Center for Industrial Research (HST-ICIR); University of Bologna; Bologna
| | - A. C. Borelli
- Department of Medical Sciences; University of Ferrara; Ferrara
| | - L. Ferraro
- Department of Life Sciences and Biotechnology; University of Ferrara; Ferrara
| | - L. Calzà
- Department of Veterinary Medical Science; University of Bologna; Bologna
- Health Science and Technologies Interdepartmental Center for Industrial Research (HST-ICIR); University of Bologna; Bologna
- Department of Pharmacy and Biotechnology; University of Bologna; Bologna Italy
| |
Collapse
|